Taivex corporate with Institute of Biotechnology and Pharmaceutical Research (IBPR) at National Health Research Institute, developing a first-in-class small molecule drug, T-1201. This drug had received 2016 Technology Achievement Award (Ministry of Economic Affairs), now get 2017 Taipei Biotech Award_ Technology Transfer Gold Medal Award (Taipei City Government).

T-1201 is a noval anti-tumor drug deliver system, that with intellectual property cover the top 10 medical countries. The development of T-1201 has open a new way for cancer treatment, and may bring the developing of anti-cancer agent with a new strategy.